Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Double-dummy Phase III Clinical Study to Evaluate the Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori

NCT05577468 is registered in ClinicalTrials.gov with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. as lead sponsor.

NCT NCT05577468
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05577468 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Double-dummy Phase III Clinical Study to Evaluate the Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori
Lead sponsor
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 30, 2022
Completion date
September 30, 2023
Enrollment
561 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection